| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9346274 | Ophthalmology | 2005 | 9 Pages |
Abstract
Results suggest that absence or delay of treatment did not influence vision-targeted HRQOL in these newly diagnosed glaucoma patients. However, visual function affected vision-targeted quality of life up to 6 years after Early Manifest Glaucoma Trial enrollment.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Leslie G. PhD, Eugene PhD, Anders MD, PhD, Bo MD, PhD, M. Cristina MD, MPH, Early Manifest Glaucoma Trial Group Early Manifest Glaucoma Trial Group,